Swedbank AB Sells 214,996 Shares of Abbott Laboratories $ABT

Swedbank AB decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 15.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,220,317 shares of the healthcare product maker’s stock after selling 214,996 shares during the quarter. Swedbank AB’s holdings in Abbott Laboratories were worth $152,894,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. Capital International Investors boosted its position in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Abbott Laboratories by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after purchasing an additional 821,325 shares during the period. Invesco Ltd. grew its stake in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on ABT shares. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Barclays reduced their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Benchmark decreased their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Jefferies Financial Group lowered their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Stock Down 0.4%

Shares of Abbott Laboratories stock opened at $87.18 on Wednesday. The company has a market capitalization of $151.84 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business has a 50-day moving average of $103.83 and a two-hundred day moving average of $115.68. Abbott Laboratories has a 1 year low of $86.16 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the business posted $1.09 EPS. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Buying and Selling

In related news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.